Major PBMs Inflated Drug Prices, Pocketing $7.3 Billion Along the Way, FTC Says
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of acquisition, earning more than $7.3 billion in revenue from 2017 to 2022, according to a report issued by the Federal Trade Commission (FTC) on Tuesday.
The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...
The U.S. Federal Trade Commission on Tuesday published the second part of its investigation into how prescription drug ...
The Massachusetts Democrat is working with a Missouri Republican, and House members from each party, to press the FTC to ...
Mattingly is an associate professor and vice chair of research in the Department of Pharmacotherapy at the University of Utah ...
Pharmacies like Snyders rely on reimbursements to make ends meet. When his business dispenses prescriptions, the repayment ...
The pharmaceutical supply chain is a sector infamous for glacially slow adjustments, lackluster reform, lack of transparency ...
At issue is the role pharmacy benefit mangers play in taking large discounts on drugs that advocates say are not passed along ...
A key provision in the new legislation could affect compensation for brokers or consultants who help employers hire pharmacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback